The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ALKERMES PLC SHS G01767105   197,252,022 7,042,200 SH   SOLE   7,042,200 0 0
AMARIN CORP PLC SPONS ADR NEW 023111206   9,607,057 10,442,453 SH   SOLE   10,442,453 0 0
BIOCRYST PHARMACEUTICALS INC COM 09058V103   5,487,000 775,000 SH   SOLE   775,000 0 0
BIOGEN INC COM 09062X103   165,257,430 643,000 SH   SOLE   643,000 0 0
GILEAD SCIENCES INC COM 375558103   68,974,776 920,400 SH   SOLE   920,400 0 0
INNOVIVA INC COM 45781M101   94,528,230 7,277,000 SH   SOLE   7,277,000 0 0
IRONWOOD PHARMACEUTICALS INC COM CL A 46333X108   157,835,700 16,390,000 SH   SOLE   16,390,000 0 0
MERSANA THERAPEUTICS INC COM 59045L106   698,500 550,000 SH   SOLE   550,000 0 0
NEUROCRINE BIOSCIENCES INC COM 64125C109   41,175,000 366,000 SH   SOLE   366,000 0 0
REGULUS THERAPEUTICS INC COM 75915K309   253,701 185,183 SH   SOLE   185,183 0 0
VOR BIOPHARMA INC COM 929033108   1,310,160 618,000 SH   SOLE   618,000 0 0